Meritage Pharma, Inc.

University of California

Dura Pharmaceuticals, Inc.

Viropharma Biologics LLC

Malcolm Hill

Elaine Phillips

Ranjan Dohil

Seema S Aceves

John Bastian

Keith Johnson

Adam Simpson

Robert K Schultz

Peter R Byron

Clyde Witham

Cynthia Licalsi

Bonnie Hepburn

Linda Gieschen

Hemant Deshmukh

Robert Farber

Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract

Provided herein are methods for treating, preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

Compositions for the treatment of gastrointestinal inflammation

Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract

Provided herein are computer-based systems, software, and methods of using the same including a daily patient questionnaire, the questionnaire comprising: a question for determining whether the patient avoided solid food; a question for determining whether the patient had difficulty swallowing solid food; a question for determining what action the patient took to correct or relieve difficulty swallowing food; a question for determining the amount of pain the patient experienced while swallowing food; and a software module configured to apply an algorithm to answers to one or more of said questions to determine a score, wherein said score illustrates one or more selected from the group consisting of: (1) severity, intensity, or frequency of patient dysphagia; (2) suitability of a patient for a particular diagnostic tool, diagnostic method, or therapy for dysphagia; and (3) efficacy of a particular therapy for dysphagia.

Systems, methods, and software for providing a patient-reported outcome measure of dysphagia patients with eosinophilic esophagitis

Corticosteroid compositions

A method for inhalation of a dry powder drug includes the steps of providing a dry powder drug composition having a drug particle size of from about 1-7 microns and a mass median aerodynamic diameter of the delivered aerosol of from about 3.5 to 5.5 microns. This composition is loaded into an inhaler which is generally flow rate independent, and with the inhaler having an inspiration flow resistance of about 0.12 to 0.21 (cmH.sub.2 O).sup.1/2 over the range of about 15-60 L/min. The patient inhales the drug composition from the inhaler with an inspiration flow rate of about 15-60 L/min, resulting in a delivery efficiency measured by respirable fraction greater than 20%.

Methods of dry powder inhalation

In a method for treating lung diseases, a drug formulation is prepared by combining micronized crystalline beclomethasone dipropionate and lactose. The drug formulation is placed into a dry powder inhaler which provides inhalable drug particles having a mass median diameter of about 0.5-5.8 microns. The inhaler is preferably largely flow rate independent. Drug and lactose particles are separated in the inhaler during inhalation, most desirably via a spinning element. Due to deep deposition, the drug particles persist in the lungs for a surprisingly long duration, increasing the therapeutic effect of each dose. The patient inhales the drug particles with an inspiratory flow rate of about 10-60 liters/minute, to produce a deep lung deposition of inhaled particles.

Pulmonary delivery of pharmaceuticals

Growing community of inventors

Solana Beach, CA, United States of America

Malcolm Hill